BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 27071307)

  • 21. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
    Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
    Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
    Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
    Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
    Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
    Mavrakis KJ; Zhu H; Silva RL; Mills JR; Teruya-Feldstein J; Lowe SW; Tam W; Pelletier J; Wendel HG
    Genes Dev; 2008 Aug; 22(16):2178-88. PubMed ID: 18708578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.
    Agarwal S; Bell CM; Taylor SM; Moran RG
    Mol Cancer Res; 2016 Jan; 14(1):66-77. PubMed ID: 26385560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance.
    Ghosh J; Kobayashi M; Ramdas B; Chatterjee A; Ma P; Mali RS; Carlesso N; Liu Y; Plas DR; Chan RJ; Kapur R
    J Clin Invest; 2016 Jul; 126(7):2621-5. PubMed ID: 27294524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
    Willems L; Chapuis N; Puissant A; Maciel TT; Green AS; Jacque N; Vignon C; Park S; Guichard S; Herault O; Fricot A; Hermine O; Moura IC; Auberger P; Ifrah N; Dreyfus F; Bonnet D; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Leukemia; 2012 Jun; 26(6):1195-202. PubMed ID: 22143671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RHEB1 insufficiency in aged male mice is associated with stress-induced seizures.
    Tian Q; Gromov P; Clement JH; Wang Y; Riemann M; Weih F; Sun XX; Dai MS; Fedorov LM
    Geroscience; 2017 Dec; 39(5-6):557-570. PubMed ID: 28891034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.
    Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X
    Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
    Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
    Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival.
    Feng Y; Wu L
    Biochem Biophys Res Commun; 2017 Feb; 483(2):897-903. PubMed ID: 28082200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
    Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
    J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTORC1 inhibitors suppress meningioma growth in mouse models.
    Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
    Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.
    Liu Q; Chen L; Atkinson JM; Claxton DF; Wang HG
    Cell Death Dis; 2016 Sep; 7(9):e2361. PubMed ID: 27607576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
    Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceramide inhibits insulin-stimulated Akt phosphorylation through activation of Rheb/mTORC1/S6K signaling in skeletal muscle.
    Hsieh CT; Chuang JH; Yang WC; Yin Y; Lin Y
    Cell Signal; 2014 Jul; 26(7):1400-8. PubMed ID: 24650522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.